Related Experiment Video

Updated: May 10, 2026

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 25, 2024

Rivaroxaban for the treatment of pulmonary embolism

Thomas Vanassche1, Peter Verhamme

  • 1Vascular Medicine and Haemostasis, Department of Cardiovascular Sciences, KU Leuven, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.

Advances in Therapy
|June 29, 2013
PubMed

Insights

Rivaroxaban, a novel oral anticoagulant, offers a new treatment option for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) and pulmonary embolism (PE). Further research is needed to optimize its use in specific clinical scenarios.

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • The introduction of novel oral anticoagulants (NOACs) marks a significant advancement in managing venous thromboembolism (VTE).
  • Rivaroxaban is the first NOAC approved for treating deep-vein thrombosis (DVT) and pulmonary embolism (PE), and for secondary VTE prevention.

Purpose of the Study:

  • To review clinical trials of rivaroxaban in VTE patients.
  • To discuss the clinical application of rivaroxaban for pulmonary embolism (PE) management.

Main Methods:

  • Review of clinical trial data for rivaroxaban in VTE.
  • Discussion of clinical use cases for PE treatment.

Main Results:

  • Rivaroxaban has demonstrated efficacy in the acute and long-term treatment of DVT and PE.
  • Rivaroxaban is approved for secondary prevention of VTE.

Conclusions:

  • Rivaroxaban simplifies the therapeutic approach to PE management.
  • Further investigation is required to establish optimal rivaroxaban use in specific clinical contexts.

More Related Videos

A Porcine Model of Acute Autologous Pulmonary Embolism07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...